. Genomic characterization of variant c.689+908G>A and effect of the change on minigenesplicing profile. A) Structure of the GFM1 gene and detail of the Sanger-sequenced region around c.689+908G>A and c.2011C>T. On the right of the figure is the family pedigree. B) Minigene analysis showing a diagram of the normal and mutant pSPL3 constructs, and gel electrophoresis of the RT-PCR products for the tested minigene. The adjacent diagram is of the variant-induced change in transcript configuration. The identity of the bands was confirmed by sequence analysis. Figure S2 . Oxygen consumption rates of fibroblasts from Pt22. The data shown are for ATPproduction-dependent, maximal respiration (Rmax) and spare capacity (Spare). Results are expressed as fold over the control concentrations and are the mean ± SD of 3-5 wells from n=2-3 independent experiments. Control values are the means of two different control cell lines. Student t test (*p<0.05).
Supplementary Tables
Abbreviations: Female (F); male (M); hours (h); days (d); weeks (wk); months (m); years (y). HPO terms follow Human Phenotype Ontology terms (https://hpo.jax.org/app/); a and b biamniotic twins (only a was considered). Abbreviations: Amino acids (Aa); Ketone Bodies (KB); AcAc (acetoacetic); hydroxy (H); methyl (M); iso (I); keto (K); Valeric (VA); butyric (B) dicarboxylic acids (Adipic and Suberic) (DC); 4-OHphenyllactic (4HPL); 4-OHphenylpyruvic (4HPP); 4-OHphenylacetic (4HPA); Fumarate (Fum); Malate (Mal); Succinate (Succ); Glutaric (GA); Glutaconic (GC); Lactic (L); Pyruvic (P); Propionic (prop); Ethylmalonic (EMA)); Increased presence of C0: free carnitine, C2: acetylcarnitine, C3: propionylcarnitine, C4: butyryl+isobutyrylcarnitine, C5DC: glutarylcarnitine, C5OH: 3-hydroxyisovalerylcarnitine, C6: hexanoylcarnitine, C6DC: adipyl+methylglutarylcarnitine, C8: octanoylcarnitine, C8:1: octenoylcarnitine, C10: decanoylcarnitine, C10:1: decenoylcarnitine, C10OH: 3hydroxydecanoylcarnitine, C16:1: palmitoleylcarnitine, C16:1OH: 3-hydroxypalmitoleylcarnitine, C18OH: 3-hydroxyestearoylcarnitine. a) Thiamine responsive lactic acidosis; Fibroblasts (FB); Muscle (M); Lymphocytes (LF); Pyruvate carboxylase (PC); Pyruvate dehydrogenase (PDH); Respiratory chain (RC); Coenzyme Q10 (COQ10). Normal lactate value in blood 1.8±0.5mmol/L; in CSF 1.6±0.3 mmol/L, and in urine 5-113 mmol/mol creatinine; Biochemical data for MDC scores: Lactate 2X in blood or CSF was scored as +2; alanine 2X was scored as +2; TCA (succinate, fumarate, malate); dicarboxylic acids (DC), 2HB, 3MGC were all scored as +1. Probably of deleterious mutation P=0.796
Gain of disorder (p = 0.0129) Loss of sheet (p = 0.0315) Loss of phosphorylation at Y210 (p = 0.038) Probability of deleterious mutation P=0.733 (Gain of relative solvent accessibility (p = 0.0215) Gain of solvent accessibility (p = 0.0306)
PROBABLY DAMAGING (1368)
In PolyPhen-2 (v2.2.2r398; http://genetics.bwh.harvard.edu/pph2/) using HumVar-trained model, scores above 0.9 were predicted as 'Probably Damaging', and those below 0.5 were predicted as 'benign". In SIFT (v1.03; http://sift.jcvi.org/), the cut-off for damaging prediction of 0.05. MutationTaster (http://www.mutationtaster.org/) employs a Bayes classifier, model simple aae (single amino acid changes) or complex aae (frameshift or premature stop codon). In PROVEAN the cut-off was 2.5. MutPred contains a general pathogenicity score (P) and a ranked list of specific molecular alterations potentially affecting the phenotype, where p is the P-value that certain structural and functional properties are impacted. Scores with P > 0.5 and p < 0.05 are actionable hypotheses; P> 0.75 and p < 0.05 are confident hypotheses, P > 0.75 and p < 0.01 are very confident hypotheses. For Panther analysis, PSEP (position-specific evolutionary preservation measured in length of time (millions of years). The thresholds chosen were: "probably damaging" (time > 450my; "possibly damaging" (450my > time > 200my) and "probably benign" (time < 200my).
